Exploring the Risk of Ocular Adverse Events Associated with Janus Kinase Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS) (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1745; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "JAK inhibitors were associated with a spectrum of reported ocular adverse events in the FAERS database. Tofacitinib demonstrated the strongest and broadest ocular safety signals, particularly for uveitis, keratitis, visual impairment, and conjunctivitis. Baricitinib and abrocitinib were associated with fewer but notable ocular signals."
Adverse events • Cardiovascular • Conjunctivitis • Immunology • Inflammatory Arthritis • Keratitis • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology • Optic Neuritis • Retinal Disorders • Rheumatoid Arthritis • Uveitis
|
|
Maria Shamsi1; Aisha Mansur2; Achsah Venite Karra3; Rita-Nour Antoine Awad4
|